Summit Therapeutics Inc. SMMT
Set alert
16.03 USD -0.17 -1.05%
At close
16.26 +0.23 +1.42%
Pre-market · Nov 2, 6:03 AM ET
15.57 Day range 16.43
12.07 52-week range 29.23
- YTD
- -8.35%
- 1 year
- -15.23%
- Open
- 16.03
- Prev close
- 16.20
- Mkt cap
- 12.79B
- Vol
- 3.51M
- Avg vol
- 6.06M
- EPS
- -1.11
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 15.57
- High
- 16.43
- Forward P/E
- -13.29
- Beta
- -1.52
- Short ratio
- 5.67
- Inst. own
- 17.58%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 2, 2026
- 50-d avg
- 15.98
- 200-d avg
- 16.18
- 1y target
- 30.24
MAX chart
Events in this range
- Oct 1, 2026Rating: Barclays · Equal-Weight → Equal-Weight
- Nov 2, 2026Earnings: —; estimate -0.28174; surprise —%
Signals (42)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 1, 2026 | 1 month ago |
| SMA: Bullish | Sep 1, 2026 | 2 months ago |
| SMA: Bearish | Jun 1, 2026 | 5 months ago |
| SMA: Bearish | May 1, 2026 | 6 months ago |
| SMA: Bullish | Apr 1, 2026 | 7 months ago |
| MACD: Sell Signal | Oct 1, 2025 | 1 year ago |
| SMA: Bearish | Sep 1, 2025 | 1 year ago |
| SMA: Bullish | Jun 1, 2025 | 1 year ago |
| SMA: Bearish | May 1, 2025 | 1 year ago |
| RSI: Overbought | Apr 1, 2025 | 1 year ago |
| RSI: Overbought | Jul 1, 2024 | 2 years ago |
| RSI: Overbought | May 1, 2024 | 2 years ago |
| SMA: Bullish | Jan 1, 2024 | 2 years ago |
| SMA: Bullish | Nov 1, 2023 | 3 years ago |
| SMA: Bearish | Aug 1, 2023 | 3 years ago |
| SMA: Bullish | Jun 1, 2023 | 3 years ago |
| SMA: Bearish | Mar 1, 2023 | 3 years ago |
| SMA: Bearish | Jan 1, 2023 | 3 years ago |
| MACD: Buy Signal | Jan 1, 2023 | 3 years ago |
| SMA: Bullish | Dec 1, 2022 | 3 years ago |
| SMA: Bullish | Dec 1, 2022 | 3 years ago |
| SMA: Bearish | Dec 1, 2021 | 4 years ago |
| MACD: Sell Signal | Nov 1, 2021 | 5 years ago |
| SMA: Bearish | Sep 1, 2021 | 5 years ago |
| SMA: Bullish | Jul 1, 2020 | 6 years ago |
| SMA: Bullish | Mar 1, 2020 | 6 years ago |
| SMA: Bullish | Dec 1, 2019 | 6 years ago |
| SMA: Bearish | Nov 1, 2019 | 7 years ago |
| SMA: Bullish | Sep 1, 2019 | 7 years ago |
| MACD: Buy Signal | Sep 1, 2019 | 7 years ago |
| SMA: Bearish | Jun 1, 2018 | 8 years ago |
| SMA: Bearish | Jun 1, 2018 | 8 years ago |
| MACD: Sell Signal | Jun 1, 2018 | 8 years ago |
| SMA: Bullish | Mar 1, 2018 | 8 years ago |
| SMA: Bearish | Feb 1, 2018 | 8 years ago |
| SMA: Bullish | Jan 1, 2018 | 8 years ago |
| SMA: Bullish | Nov 1, 2017 | 9 years ago |
| SMA: Bearish | Oct 1, 2017 | 9 years ago |
| SMA: Bearish | Oct 1, 2017 | 9 years ago |
| SMA: Bullish | Jan 1, 2017 | 9 years ago |
| SMA: Bearish | Dec 1, 2016 | 9 years ago |
| SMA: Bullish | Sep 1, 2016 | 10 years ago |
Key statistics
- Market cap
- 12.45B
- Enterprise value
- 12.25B
- Trailing P/E
- 0.00
- Forward P/E
- -13.29
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 19.65
- EPS (TTM)
- -1.11
- Beta
- -1.52
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -139.68M
- Total cash
- 690.68M
- Total debt
- 20.38M
- Return on equity
- -192.50%
- Shares outstanding
- 797.75M
- Short % of float
- 26.14%
- 50-day average
- 15.98
- 200-day average
- 16.18
Analyst view
Consensus: buy
Buy
Price target (mean) 30.24 +88.7% upside
Now 16.03
- Target (low)
- 11.92
- Target (mean)
- 30.24
- Target (high)
- 43.80
Ratings (0m) 17 11 buy · 6 hold · 0 sell
- Strong buy1
- Buy10
- Hold6
- Sell0
- Strong sell0
Next earnings
Nov 2, 2026
Expected Nov 2, 2026. Consensus EPS estimate -0.20808.
Financials — quick view
SMMT Revenue — quarterly 0
SMMT Net income — quarterly -215.70M
SMMT EPS — quarterly -0.003
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 2, 2026 | Sep 30, 2026 | -0.28174 | — | — | — |
| Jul 23, 2026 | Jun 30, 2026 | -0.27439 | -0.28 | -0.01 | -2.04% |
| Apr 30, 2026 | Mar 31, 2026 | -0.33 | -0.24 | +0.09 | +27.27% |
| Feb 23, 2026 | Dec 31, 2025 | -0.10264 | -0.29 | -0.19 | -182.54% |
| Oct 20, 2025 | Sep 30, 2025 | -0.17577 | -0.31 | -0.13 | -76.37% |
| Aug 11, 2025 | Jun 30, 2025 | -0.09081 | -0.76 | -0.67 | -736.91% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 1, 2026 | Barclays | main | Equal-Weight | Equal-Weight |
| Sep 29, 2026 | Citigroup | main | Buy | Buy |
| Sep 23, 2026 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Sep 9, 2026 | Jefferies | up | Hold | Buy |
| Aug 26, 2026 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Aug 25, 2026 | Bernstein | up | Underperform | Market Perform |
About Summit Therapeutics Inc.
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- smmttx.com
News
- Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts
- Breakfast News: Science Strikes Back at Cancer
- Summit Therapeutics Announces Clinical Trial Collaboration With The ECOG-ACRIN Cancer Research Group To Evaluate Ivonescimab In A Phase II/III Study In Biliary Tract Cancer
- Chip Stocks Slide as South Korea's KOSPI Plunges, J&J Sinks 6%: Stock Market Today
- 10 Health Care Stocks With Whale Alerts In Today’s Session
- Stock Market Today: S&P 500, Russell 2000 Fall as 30-Year Yield Hits 5.7%
- Amazon, Alphabet, Tesla Stock Rises: Robinhood Traders Sell Anyway
- AstraZeneca, Daiichi Sankyo Expand Cancer Push Through Summit Partnership
Your note
Sign in to keep a note on SMMT — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Baker Bros. Advisors, LP | 4.10% | 32,786,348 | 511.63M | Jun 29, 2026 |
| FMR, LLC | 1.26% | 10,043,947 | 156.74M | Jun 29, 2026 |
| State Street Corporation | 1.19% | 9,536,796 | 148.82M | Jun 29, 2026 |
| Blackrock Inc. | 1.19% | 9,529,041 | 148.70M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 0.72% | 5,734,484 | 89.49M | Jun 29, 2026 |
| UBS Group AG | 0.65% | 5,233,798 | 81.67M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 0.46% | 3,707,548 | 57.86M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 0.45% | 3,635,145 | 56.73M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 0.33% | 2,667,317 | 41.62M | Jun 29, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 0.32% | 2,531,231 | 39.50M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 0.26% | 2,047,862 | 31.96M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.22% | 1,778,361 | 27.75M | Jun 29, 2026 |